Mounjaro and OzemPIC Get Who Who

The World Health Organization has added GLP -1 (peptide -1 glucagon) to diabetes to the basic medicine list, joining treatments for cystic fibrosis and cancer. This step aims to improve global access to these high -cost treatments, in the wake of a pattern as the integration into the list historically increased the availability of the poorest countries, as it appears with HIV treatments in the early first decade of the twentieth century.

The basic drug list of WhO’s Essential 523 adult properties and 374 for children, with highlighting the treatments you see is necessary for all working health systems. “Instead of leaving the price an unqualified factor, the committee looks at the inclusion of the list of the basic drugs as a potential incentive to reach,” Dr. Lorenzo Mawda, President of the World Health Organization, who supervises the list, told Reuters.

The active ingredients were added in Novo Nordisk’s OzemPIC and ELI Lilly’s Mountjaro to treat type 2 diabetes in patients with firm cardiovascular disease, chronic kidney disease or obesity. While it was originally developed for diabetes, these drugs also gained popularity as weight loss treatments under different commercial names. Whoever did not only include obesity, as I refrained from doing it in 2023.

The Experts Committee said that the decision provides clear guidelines that patients will benefit more than treatments. The World Health Organization noted that “the prices of high medicines, such as the semules, and Terzopatid, limit access,” and encouraged the makers of small drugs to start production with the end of patents in the next year.

A spokesman for the Novo Nordisk said the company is committed to the support of wider access to its treatments. Elie Lily replied this, noting that the copies outside the joy or public of these drugs “may be better candidates to meet the patient’s needs and provide cost savings in low resource settings.”

Globally, the World Health Organization stated that more than 800 million people lived with diabetes in 2022, with more than a billion people affected by obesity. A separate World Health Organization indicated earlier this year to recommend obesity in future guidance.

Besides the GLP-1 drugs, the World Health Organization of the World Health Organization added the compound therapy to Vertex Pharmaceuticals for cystic fibrosis, Tikafta/Kaftrio, and MERC Cancer Cancer Cancer Cancer Cancer Cancer, Colon and Recalment. While activists criticized the high price of Tricafta, the drug maker refused to comment on its inclusion. Merck confirmed her commitment to reaching patients in need.

The list also includes the NOVO Nordisk, Eli Lilly and other manufacturers of type 1, type 2 and pregnancy, which enhances the focus on the World Health Organization on expanding access to basic treatments around the world.

(With Reuters inputs)